Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib : comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
Solis-Hernandez, Mª Pilar (Hospital Universitario Central de Asturias)
Fernandez del Valle, Ana (Hospital Universitario Central de Asturias)
Carmona-Bayonas, Alberto (Hospital General Universitario Morales Meseguer (Múrcia))
García-Carbonero, Rocío (Hospital Universitario 12 de Octubre (Madrid))
Custodio, Ana (Hospital Universitario La Paz (Madrid))
Benavent, Marta (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia))
Alonso-Gordoa, Teresa (Hospital Universitario Ramón y Cajal (Madrid))
Nuñez-Valdovino, Bárbara (Hospital Clinico Universidad de Chile (Santiago de Xile, Xile))
Sanchez Canovas, Manuel (Hospital General Universitario Morales Meseguer (Múrcia))
Matos, Ignacio (Hospital Universitari Vall d'Hebron)
Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa))
Lopez, Carlos (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Viudez, Antonio (Complejo Hospitalario de Navarra)
Izquierdo, Marta (Hospital Universitario Central de Asturias)
Calvo-Temprano, David (Hospital Universitario Central de Asturias)
Grande, Enrique (MD Anderson Cancer Center)
Capdevila Castillón, Jaume (Hospital Universitari Vall d'Hebron)
Jimenez-Fonseca, Paula (Hospital Universitario Central de Asturias)
Universitat Autònoma de Barcelona
Vall d'Hebron Institut d'Oncologia

Fecha:	2019
Resumen:	The purpose of our study was to analyse the usefulness of Choi criteria versus RECIST in patients with pancreatic neuroendocrine tumours (PanNETs) treated with sunitinib. A multicentre, prospective study was conducted in 10 Spanish centres. Computed tomographies, at least every 6 months, were centrally evaluated until tumour progression. One hundred and seven patients were included. Median progression-free survival (PFS) by RECIST and Choi were 11. 42 (95% confidence interval [CI], 9. 7-15. 9) and 15. 8 months (95% CI, 13. 9-25. 7). PFS by Choi (Kendall's τ = 0. 72) exhibited greater correlation with overall survival (OS) than PFS by RECIST (Kendall's τ = 0. 43). RECIST incorrectly estimated prognosis in 49. 6%. Partial response rate increased from 12. 8% to 47. 4% with Choi criteria. Twenty-four percent of patients with progressive disease according to Choi had stable disease as per RECIST, overestimating treatment effect. Choi criteria predicted PFS/OS. Changes in attenuation occurred early and accounted for 21% of the variations in tumour volume. Attenuation and tumour growth rate (TGR) were associated with improved survival. Choi criteria were able to capture sunitinib's activity in a clinically significant manner better than RECIST; their implementation in standard clinical practice shall be strongly considered in PanNET patients treated with this drug.
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Cancer imaging ; Neuroendocrine cancer
Publicado en:	British Journal of Cancer, Vol. 121 (september 2019) , p. 537-544, ISSN 1532-1827

DOI: 10.1038/s41416-019-0558-7
PMID: 31477779

8 p, 518.2 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados